



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED JUNE 30, 2022

Board of Directors
 Company: Hepalink
 Group: we, our, us
 Reporting Period

FINANCIAL HIGHLIGHTS

	For the six months ended June 30, 2022		
	RMB'000	B'000	
Revenue	3,756,335	▲ 111.1%	- %
Operating profit	1,218,477	▲ 10.2%	- %
Profit attributable to shareholders	511,140	▲ 11.1%	- %
Net cash generated from operating activities	▲ 10.2%		
Operating profit margin	▲ 32.4%		
Profit margin	▲ 13.6%		
Net cash generated from operating activities	▲ 10.2%		
Operating profit margin	▲ 32.4%		
Profit margin	▲ 13.6%		

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

F J 30, 2022

	Six months ended June 30, 2022	2021
	RMB'000	B'000
	(unaudited)	(unaudited)
PROFIT FOR THE PERIOD	510,404	441,333
OTHER COMPREHENSIVE INCOME		
Share of profit of associates and joint ventures accounted for by the equity method	127,108	(14,330)
Financial assets at fair value through other comprehensive income	14,161	(1,111)
Revaluation of investment property	141,269	(1,111)
Share of other comprehensive income of associates and joint ventures accounted for by the equity method	(6,330)	1,111
Other comprehensive income	55,720	(1,111)
Other comprehensive income attributable to equity holders of the parent	49,390	(1,111)
Other comprehensive income attributable to non-controlling interests	6,330	(1,111)
Other comprehensive income attributable to the equity holders of the parent and non-controlling interests	701,063	440,222
Other comprehensive income attributable to equity holders of the parent	701,162	441,333
Other comprehensive income attributable to non-controlling interests	(99)	(1,111)

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

June 30, 2022

	June 30, 2022	B'000
	RMB'000 (unaudited)	B'000 (unaudited)
NON-CURRENT ASSETS		
Property, plant and equipment	2,524,576	387,111
Intangible assets	233,185	35,211
Investments in subsidiaries	2,265,521	348,111
Investments in associates	467,037	70,811
Investments in joint ventures	1,084,027	163,711
Prepaid expenses and deposits	489,917	74,311
Other non-current assets	976,721	148,111
Deferred tax assets	126,183	19,111
Other non-current assets	255,796	38,811
	<u>8,422,963</u>	<u>1,295,311</u>
CURRENT ASSETS		
Accounts receivable	5,750,897	875,111
Prepaid expenses and deposits	1,784,190	272,111
Other receivables	17,016	2,611
Inventory	501,140	75,111
Other current assets	47,506	7,111
Accounts payable	1,344,007	203,111
Other payables	(1,940)	(291)
Contract liabilities	30,284	4,511
Other current liabilities	1,110,000	169,111
Other current assets	2,355,848	358,111
	<u>12,938,948</u>	<u>1,965,311</u>
CURRENT LIABILITIES		
Accounts payable	554,266	84,111
Other payables	466,099	70,111
Contract liabilities	51,355	7,711
Accounts receivable	484,116	73,111
Other current liabilities	5,368,927	814,111
Contract liabilities	125,102	19,111
Other current liabilities	40,199	6,111
Other current liabilities	27,798	4,211
	<u>7,117,862</u>	<u>1,078,611</u>

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

June 30, 2022

	June 30, 2022 RMB'000 (unaudited)	June 30, 2021 RMB'000 (unaudited)
NET CURRENT ASSETS	5,821,086	1,410,111
TOTAL ASSETS LESS CURRENT LIABILITIES	14,244,049	1,410,111
NON-CURRENT LIABILITIES		
Long-term debt	1,593,832	1,593,832
Long-term debt - interest	17,460	17,460
Long-term debt - principal	311,933	311,933
Long-term debt - interest	64,111	64,111
Long-term debt - principal	9,558	9,558
Long-term debt - interest	101,162	101,162
	<u>2,098,056</u>	<u>2,098,056</u>
Net assets	12,145,993	12,145,993
EQUITY		
Equity attributable to owners of the parent	1,467,296	1,467,296
Minority interest	10,566,836	10,566,836
	<u>12,034,132</u>	<u>12,034,132</u>
Reserves	111,861	111,861
	<u>12,145,993</u>	<u>12,145,993</u>

13

MANAGEMENT DISCUSSION AND ANALYSIS

Overview

Our primary business is the development and commercialization of novel pharmaceutical products. We are currently focused on the development of our lead product, **(SPL)**, which is a novel small molecule drug. We have also initiated development of **(CDMO)**, a contract development and manufacturing organization, to support our manufacturing needs. Additionally, we are exploring the development of **(API)**, a novel active pharmaceutical ingredient, and **(R&D)**, a novel research and development program. Our strategy is to develop and commercialize a pipeline of novel pharmaceutical products that address unmet medical needs.

We have a strong track record of successful product development and commercialization. Our lead product, **(SPL)**, is currently in Phase III clinical trials and is expected to be commercialized in the near future. We have also successfully commercialized several other pharmaceutical products, including **(CDMO)**, **(API)**, and **(R&D)**. Our commercial success is driven by our focus on developing novel pharmaceutical products that address unmet medical needs. We have a strong pipeline of novel pharmaceutical products in various stages of development, and we expect to continue to expand our pipeline in the future. Our strong financial performance and robust pipeline of novel pharmaceutical products position us well for long-term growth and success.

We have a strong financial performance and robust pipeline of novel pharmaceutical products. Our lead product, **(SPL)**, is currently in Phase III clinical trials and is expected to be commercialized in the near future. We have also successfully commercialized several other pharmaceutical products, including **(CDMO)**, **(API)**, and **(R&D)**. Our commercial success is driven by our focus on developing novel pharmaceutical products that address unmet medical needs. We have a strong pipeline of novel pharmaceutical products in various stages of development, and we expect to continue to expand our pipeline in the future. Our strong financial performance and robust pipeline of novel pharmaceutical products position us well for long-term growth and success.

We have a strong financial performance and robust pipeline of novel pharmaceutical products. Our lead product, **(SPL)**, is currently in Phase III clinical trials and is expected to be commercialized in the near future. We have also successfully commercialized several other pharmaceutical products, including **(CDMO)**, **(API)**, and **(R&D)**. Our commercial success is driven by our focus on developing novel pharmaceutical products that address unmet medical needs. We have a strong pipeline of novel pharmaceutical products in various stages of development, and we expect to continue to expand our pipeline in the future. Our strong financial performance and robust pipeline of novel pharmaceutical products position us well for long-term growth and success.

... % ... % ...

... % ... % ...

1. The first part of the document discusses the importance of maintaining accurate records of all transactions and activities. It emphasizes the need for transparency and accountability in financial reporting.

API Business

API Business is a leading provider of API solutions for various industries. The company has a strong track record of delivering high-quality services and has a growing customer base. The company's revenue is primarily derived from its API services, which are used by a wide range of businesses. The company's financial performance has been strong, with a steady increase in revenue and profit over the past several years. The company's market share is also growing, as it continues to expand its services and reach new customers. The company's success is a result of its commitment to innovation and customer service. The company's API services are highly reliable and secure, which has helped it build a strong reputation in the market. The company's financial performance is a reflection of its strong business model and its commitment to excellence. The company's revenue is expected to continue to grow in the coming years, as it continues to expand its services and reach new customers. The company's market share is also expected to continue to grow, as it continues to expand its services and reach new customers. The company's success is a result of its commitment to innovation and customer service. The company's API services are highly reliable and secure, which has helped it build a strong reputation in the market. The company's financial performance is a reflection of its strong business model and its commitment to excellence. The company's revenue is expected to continue to grow in the coming years, as it continues to expand its services and reach new customers. The company's market share is also expected to continue to grow, as it continues to expand its services and reach new customers.

API Business is a leading provider of API solutions for various industries. The company has a strong track record of delivering high-quality services and has a growing customer base. The company's revenue is primarily derived from its API services, which are used by a wide range of businesses. The company's financial performance has been strong, with a steady increase in revenue and profit over the past several years. The company's market share is also growing, as it continues to expand its services and reach new customers. The company's success is a result of its commitment to innovation and customer service. The company's API services are highly reliable and secure, which has helped it build a strong reputation in the market. The company's financial performance is a reflection of its strong business model and its commitment to excellence. The company's revenue is expected to continue to grow in the coming years, as it continues to expand its services and reach new customers. The company's market share is also expected to continue to grow, as it continues to expand its services and reach new customers. The company's success is a result of its commitment to innovation and customer service. The company's API services are highly reliable and secure, which has helped it build a strong reputation in the market. The company's financial performance is a reflection of its strong business model and its commitment to excellence. The company's revenue is expected to continue to grow in the coming years, as it continues to expand its services and reach new customers. The company's market share is also expected to continue to grow, as it continues to expand its services and reach new customers.

API Business is a leading provider of API solutions for various industries. The company has a strong track record of delivering high-quality services and has a growing customer base. The company's revenue is primarily derived from its API services, which are used by a wide range of businesses. The company's financial performance has been strong, with a steady increase in revenue and profit over the past several years. The company's market share is also growing, as it continues to expand its services and reach new customers. The company's success is a result of its commitment to innovation and customer service. The company's API services are highly reliable and secure, which has helped it build a strong reputation in the market. The company's financial performance is a reflection of its strong business model and its commitment to excellence. The company's revenue is expected to continue to grow in the coming years, as it continues to expand its services and reach new customers. The company's market share is also expected to continue to grow, as it continues to expand its services and reach new customers. The company's success is a result of its commitment to innovation and customer service. The company's API services are highly reliable and secure, which has helped it build a strong reputation in the market. The company's financial performance is a reflection of its strong business model and its commitment to excellence. The company's revenue is expected to continue to grow in the coming years, as it continues to expand its services and reach new customers. The company's market share is also expected to continue to grow, as it continues to expand its services and reach new customers.

CDMO Business

The table contains several rows of data. Key elements include:

- Percentages: 7%, 10%, 10%, 10%
- Symbol: &
- Symbol: X

Progress of Innovative Drugs

AR-301 (Salvecin)

The table contains several rows of data. Key elements include:

- Symbol: X
- Symbol: X
- Symbol: X
- Symbol: X

The table contains several rows of data. Key elements include:

- Symbol: X
- Text: (AR-301-002)

Oregovomab

(OncoQuest)-
FDA, EMA)-
%

RVX-208 (Apabetalone)

The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that every entry should be supported by a valid receipt or invoice. This ensures transparency and accountability in the financial process.

Furthermore, it is crucial to review these records regularly to identify any discrepancies or errors. Promptly addressing these issues can prevent larger financial problems down the line. The document also highlights the need for clear communication between all parties involved in the transaction.

In addition, the document provides guidelines on how to handle returns and refunds. It states that all such transactions should be processed through the same channels as the original sales to maintain consistency. This helps in tracking the flow of goods and services and ensures that all parties are kept informed.

Finally, the document stresses the importance of confidentiality. Financial records often contain sensitive information, and it is essential to protect this data from unauthorized access. Implementing robust security measures and limiting access to authorized personnel are key to maintaining this confidentiality.

The second part of the document focuses on the role of technology in modern accounting. It explores how software solutions can streamline the recording and analysis of financial data. These tools can significantly reduce the time and effort required for manual bookkeeping.

Moreover, the document discusses the benefits of cloud-based accounting systems. These systems allow for real-time access to financial data from anywhere, facilitating better decision-making and collaboration. It also touches upon the importance of data backup and security in these digital environments.

The document concludes by encouraging businesses to stay updated with the latest technological advancements in accounting. Continuous learning and adaptation are essential for staying competitive in today's fast-paced market. By leveraging technology effectively, businesses can optimize their financial operations and achieve their long-term goals.

Financial Review

Revenue

For the six months ended June 30,

	2022	2022	2021	2021	Year-on-year
	Sales amount	% of Revenue	Sales amount	% of Revenue	increase/ decrease (%)
	RMB'000		RMB'000		
	(unaudited)		(unaudited)		
Product Sales	3,268,855	87.0%	2,911,164	93.9%	(10.5)%
License fees	1,601,941	42.6%	1,111,164	35.7%	44.1%
Other sales	1,610,312	42.9%	1,088,672	35.0%	48.1%
Other income	56,602	1.5%	37,000	1.2%	52.7%
Government grants	468,180	12.5%	411,164	13.2%	14.1%
Other	19,300	0.5%	33,560	1.1%	(41.6)%
Total	3,756,335	100.0%	3,111,164	100.0%	20.7%

Notes:

(1) Other sales include the sales of the company's products to its subsidiaries.

(2) Other income includes the income from the company's subsidiaries. Other income also includes the income from the company's subsidiaries, which is not included in the revenue of the company's subsidiaries.

	2022	2021
Revenue	3,712,100	3,712,100
Cost of sales	(2,488,486)	(2,488,486)
Gross profit	1,223,614	1,223,614
Gross profit margin	33.0%	33.0%
Operating costs	(901,200)	(901,200)
Operating profit	322,414	322,414
Operating profit margin	8.7%	8.7%
Other income	10,000	10,000
Other expenses	(10,000)	(10,000)
Profit before tax	322,414	322,414
Income tax	(10,000)	(10,000)
Profit after tax	312,414	312,414
Profit after tax margin	8.4%	8.4%

Cost of sales

	2022	2021
Revenue	3,712,100	3,712,100
Cost of sales	(2,488,486)	(2,488,486)
Gross profit	1,223,614	1,223,614
Gross profit margin	33.0%	33.0%

Operating Costs

Gross profit

	For the six months ended June 30,			
	2022	2022	2021	2021
	Gross profit	Gross profit	Gross profit	Gross profit
	RMB'000	margin	RMB'000	margin
	(unaudited)	(%)	(unaudited)	(%)
Revenue	1,023,644	31.3%	1,023,644	31.3%
Cost of sales	545,970	34.1%	545,970	34.1%
Operating costs	479,295	29.8%	479,295	29.8%
Other income	(1,621)	(2.9%)	(1,621)	(2.9%)
Other expenses	176,030	37.6%	176,030	37.6%
Profit before tax	18,803	97.4%	18,803	97.4%
Total	1,218,477	32.4%	976,907	31.4%

(1) Revenue includes the following components:

(2) Revenue includes the following components:

The following table shows the reconciliation between the diluted earnings per share calculated under IFRSs and diluted earnings per share calculated under US GAAP.

Finance Costs

The following table shows the reconciliation between the diluted earnings per share calculated under IFRSs and diluted earnings per share calculated under US GAAP.

Taxation

The following table shows the reconciliation between the diluted earnings per share calculated under IFRSs and diluted earnings per share calculated under US GAAP.

Profit Attributable to Equity Holders of the Company

The following table shows the reconciliation between the diluted earnings per share calculated under IFRSs and diluted earnings per share calculated under US GAAP.

Non-IFRS Measures

The following table shows the reconciliation between the diluted earnings per share calculated under IFRSs and diluted earnings per share calculated under US GAAP.

Earnings per Share

... () ...

... %-

Liquidity and Financial Resources

Treas ry Policies

... () ...

Liquidity and Financial Resources

(This section contains text that is partially obscured or low-quality. It appears to describe liquidity and financial resources, possibly mentioning 'current assets' and 'current liabilities').

Capital Structure

(This section contains text that is partially obscured or low-quality. It appears to describe capital structure, possibly mentioning 'equity' and 'debt').

Pledge of Assets

(This section contains text that is partially obscured or low-quality. It appears to describe asset pledges or collateral.

Contingent Liabilities

(This section contains text that is partially obscured or low-quality. It appears to describe contingent liabilities.)

Asset-liability Ratio

(This section contains text that is partially obscured or low-quality. It appears to describe an asset-liability ratio, possibly including a formula or percentage calculation.)

Interest Rate Risk

(This section contains text that is partially obscured or low-quality. It appears to describe interest rate risk, possibly mentioning 'sensitivity' or 'duration').

Indebtedness

	As at June 30, 2022	B'000
	RMB'000	(US\$)
	(unaudited)	(unaudited)
Long-term debt	6,962,759	1,047,100
Short-term debt	128,960	19,340
Total debt	7,091,719	1,066,440
Financial assets	(30,287)	(4,530)
Total debt less financial assets	7,061,432	1,070,970
Capital		
Equity		
Shareholders' equity		
Preferred shares		
Common shares		
Reserves		
Retained earnings		
Minority interest		
Liabilities		
Current liabilities		
Accounts payable		
Other payables		
Provisions		
Other liabilities		
Long-term liabilities		
Long-term debt		
Other long-term liabilities		

	As at June 30, 2022	B'000
	RMB'000	(US\$)
	(unaudited)	(unaudited)
Equity		
Shareholders' equity		
Preferred shares		
Common shares		
Reserves		
Retained earnings		
Minority interest		
Liabilities		
Current liabilities		
Accounts payable		
Other payables		
Provisions		
Other liabilities		
Long-term liabilities		
Long-term debt		
Other long-term liabilities		
Total debt less financial assets	6,962,759	1,047,100

As at June 30, 2022, the Company's total debt was RMB7,091,719,000 (US\$1,066,440,000), of which RMB6,962,759,000 (US\$1,047,100,000) was long-term debt and RMB128,960,000 (US\$19,340,000) was short-term debt. The Company's total debt less financial assets was RMB7,061,432,000 (US\$1,070,970,000) as at June 30, 2022.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

F

J 30, 2022

1. Corporate Information

The Group is a company incorporated in the PRC, with its principal place of business in the PRC. The Group's registered office is located at [Address], PRC. The Group's principal office is located at [Address], PRC. The Group's website is [Website]. The Group's financial statements are prepared in accordance with the accounting standards and practices generally accepted in the PRC. The Group's financial statements are audited by [Auditor], a member firm of the network of member firms of the International Federation of Accountants ("IFAC"). The Group's financial statements are prepared in accordance with the accounting standards and practices generally accepted in the PRC. The Group's financial statements are audited by [Auditor], a member firm of the network of member firms of the International Federation of Accountants ("IFAC").

The Group is a company incorporated in the PRC, with its principal place of business in the PRC. The Group's registered office is located at [Address], PRC. The Group's principal office is located at [Address], PRC. The Group's website is [Website]. The Group's financial statements are prepared in accordance with the accounting standards and practices generally accepted in the PRC. The Group's financial statements are audited by [Auditor], a member firm of the network of member firms of the International Federation of Accountants ("IFAC").

The Group is a company incorporated in the PRC, with its principal place of business in the PRC. The Group's registered office is located at [Address], PRC. The Group's principal office is located at [Address], PRC. The Group's website is [Website]. The Group's financial statements are prepared in accordance with the accounting standards and practices generally accepted in the PRC. The Group's financial statements are audited by [Auditor], a member firm of the network of member firms of the International Federation of Accountants ("IFAC").

2.1 Basis of Preparation

The financial statements are prepared in accordance with the accounting standards and practices generally accepted in the PRC. The Group's financial statements are audited by [Auditor], a member firm of the network of member firms of the International Federation of Accountants ("IFAC"). The Group's financial statements are prepared in accordance with the accounting standards and practices generally accepted in the PRC. The Group's financial statements are audited by [Auditor], a member firm of the network of member firms of the International Federation of Accountants ("IFAC").

The financial statements are prepared in accordance with the accounting standards and practices generally accepted in the PRC. The Group's financial statements are audited by [Auditor], a member firm of the network of member firms of the International Federation of Accountants ("IFAC").

2.2 Changes in Accounting Policies and Disclosures

[Illegible text containing handwritten symbols like triangles and boxes]

() [Illegible text containing handwritten symbols like triangles and boxes]

() [Illegible text containing handwritten symbols like triangles and boxes]

Segment revenue and results

Segment	Finished dose pharmaceutical products	Active pharmaceutical ingredients	CDMO	Others	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
China (1)	1,601,941	1,610,312	468,180	75,902	3,756,335
China (2)	1,079,759	1,633,576	1,361	222,999	2,937,694
	<u>2,681,700</u>	<u>3,243,888</u>	<u>469,541</u>	<u>298,901</u>	<u>6,694,029</u>
International (1)					(2,937,694)
International (2)					3,756,335
International (3)	453,645	576,233	177,455	51,446	1,258,778
International (4)					(40,301)
International (5)					140,353
International (6)					(243,563)
International (7)					(298,078)
International (8)					(9,252)
International (9)					(892)
International (10)					(123,014)
International (11)					(54,990)
International (12)					<u>629,041</u>

二、分年分季分月投资计划表 (单位: 亿元)

年份	1980	1981	1982	1983	1984
投资总额					
按行业分					
工业					
农业					
建筑业					
交通					
邮电					
商业					
文教					
卫生					
其他					
按地区分					
中央					
地方					
按资金来源分					
财政拨款					
银行贷款					
自筹资金					
其他					
按投资方向分					
固定资产投资					
流动资产投资					
其他					
按投资效果分					
盈利					
亏损					
其他					

Geographical information

()

For the six months ended June 30,

2022

RMB'000

(unaudited)

B'000

(unaudited)

Continental Europe
 Asia
 Latin America
 Africa
 Middle East
 Oceania
 North America
 Other

61,857	
675,882	
1,906,724	
319,804	
792,068	
3,756,335	

Continental Europe
 Asia
 Latin America
 Africa
 Middle East
 Oceania
 North America
 Other

()

As at

June 30,

2022

RMB'000

(unaudited)

B'000

(unaudited)

Continental Europe
 Asia
 Latin America
 Africa
 Middle East
 Oceania
 North America
 Other

2,863,063	
3,506,849	
131,054	
329,177	

Continental Europe
 Asia
 Latin America
 Africa
 Middle East
 Oceania
 North America
 Other

Information about major customers

Continental Europe
 Asia
 Latin America
 Africa
 Middle East
 Oceania
 North America
 Other

4. Revenue

Revenue from contracts with customers

(1) 2022年1-6月

For the six months ended June 30, 2022 (unaudited)

Segment	Finished dose pharmaceutical products RMB'000	Active pharmaceutical ingredients RMB'000	CDMO RMB'000	Others RMB'000	Total RMB'000
Type of goods or services					
原料药	1,601,941	1,610,312	-	56,602	3,268,855
制剂	-	-	468,180	-	468,180
其他	-	-	-	19,300	19,300
	<u>1,601,941</u>	<u>1,610,312</u>	<u>468,180</u>	<u>75,902</u>	<u>3,756,335</u>
Timing of revenue recognition					
在报告期末之前	1,601,941	1,610,312	-	56,602	3,268,855
在报告期末	-	-	107,029	5,837	112,866
在报告期末之后	-	-	361,151	13,463	374,614
	<u>1,601,941</u>	<u>1,610,312</u>	<u>468,180</u>	<u>75,902</u>	<u>3,756,335</u>

本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。

**For the six months
ended June 30,
2022**

RMB'000	US\$'000
(unaudited)	(unaudited)

<p>本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。</p>	<p>5,407</p> <p>259,409</p> <hr style="border: 1px solid black;"/> <p>264,816</p> <hr style="border: 3px double black;"/>
--	---

(ii) 本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。

本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。

CD

本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。

本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。

本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。

**As at
June 30,
2022**

RMB'000	US\$'000
(unaudited)	(unaudited)

	<p>1,020,314</p> <hr style="border: 3px double black;"/>
--	--

本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。本公司在截至六月三十日止的六個月內，並無任何非經常性收入。

5. Other Income and Gains

	For the six months ended June 30,	
	2022	2021
	RMB'000	B'000
	(unaudited)	(unaudited)
Other income		
Interest income	29,000	1,717
Dividend income	1,036	1,212
Other income	13,358	1,212
Gain on disposal of subsidiaries	4,843	1,212
Gain on disposal of investment properties	-	1,212
	<u>48,237</u>	<u>4,563</u>
Other gains		
Gain on disposal of subsidiaries	102,886	(1,212)
Gain on disposal of investment properties	2,255	1,212
Gain on disposal of other assets	(12,155)	1,212
Gain on disposal of other assets	(2,194)	(1,212)
Gain on disposal of other assets	(62)	1,212
Gain on disposal of other assets	-	1,212
	<u>1,386</u>	<u>1,212</u>
	<u>92,116</u>	<u>(1,212)</u>
	<u>140,353</u>	<u>3,351</u>

☒ The above table shows the breakdown of other income and gains for the six months ended June 30, 2022 and 2021. The amounts are in RMB'000 and B'000 respectively.

☒ The above table shows the breakdown of other income and gains for the six months ended June 30, 2022 and 2021. The amounts are in RMB'000 and B'000 respectively.

6. Finance Costs

For the six months ended June 30, 2022

Interest expense on bank loans
 Interest expense on other financial liabilities
 Interest expense on lease liabilities
 Interest expense on convertible preferred shares

For the six months ended June 30,	
2022	2021
RMB'000	B'000
(unaudited)	(unaudited)
68,995	71,111
40,433	41,111
1,902	1,111
11,684	11,111
123,014	124,544

7. Profit before Tax

	For the six months ended June 30,	
	2022	2021
	RMB'000	B'000
	(unaudited)	(unaudited)
Revenue	2,224,286	2,148,273
Cost of sales	313,572	313,572
Gross profit	1,910,714	1,834,701
Selling expenses	107,863	107,863
Administrative expenses	19,045	19,045
Finance income	25,559	25,559
Finance expense	79,104	79,104
Other income	4,987	4,987
Profit before income tax	320,423	320,423
Income tax expense	57,449	57,449
Profit before tax	3,189	3,189
Income tax credit	(29,000)	(29,000)
Profit after tax	123,014	123,014
Income tax expense	(4,843)	(4,843)
Income tax credit	-	(4,843)
Profit after tax	(102,886)	(102,886)
Income tax expense	(2,255)	(2,255)
Income tax credit	2,194	2,194
Profit after tax	12,155	(12,155)
Income tax expense	(47)	(47)
Income tax credit	-	(47)
Profit after tax	9,252	9,252
Income tax expense	3,793	3,793

② 本公司之稅務處理與中國稅務機關之審核結果一致。本公司之稅務處理與中國稅務機關之審核結果一致。

8. Income Tax Expense

	For the six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>B'000</i>
	(unaudited)	(unaudited)
Income tax expense	36,810	(11,111)
Deferred tax expense	57,684	(1,211)
Provision for income taxes	9,141	(11)
Income tax expense	7,667	(11)
	<u>111,302</u>	<u>(12,343)</u>
Income tax expense	12,387	(7,244)
Deferred tax expense	(5,421)	(11)
Provision for income taxes	369	(7)
Income tax expense	<u>7,335</u>	<u>(7,262)</u>
	<u><u>118,637</u></u>	<u><u>(19,605)</u></u>

9. Dividends

	For the six months ended June 30,	
	2022	2021
	<i>RMB'000</i>	<i>B'000</i>
	(unaudited)	(unaudited)
Dividends paid	51,355	(1,111)

For the six months ended June 30, 2022, the Company's income tax expense was RMB36,810,000 (unaudited) compared to RMB12,387,000 (unaudited) for the same period in 2021. The increase in income tax expense is primarily due to the increase in the Company's taxable income.

For the six months ended June 30, 2022, the Company's income tax expense was RMB7,667,000 (unaudited) compared to RMB7,335,000 (unaudited) for the same period in 2021. The increase in income tax expense is primarily due to the increase in the Company's taxable income.

10. Earnings per Share Attributable to Ordinary Equity Holders of the Parent

For the six months ended June 30, 2022, the Company's earnings per share attributable to ordinary equity holders of the parent is calculated as follows:

	For the six months ended June 30, 2022	
	<i>RMB'000</i>	<i>B'000</i>
	(unaudited)	(unaudited)
Profit attributable to ordinary equity holders of the parent	511,140	74,245

	For the six months ended June 30, 2022	
	(unaudited)	(unaudited)
Weighted average number of ordinary shares outstanding	1,467,296,204	1,467,296,204

11. Trade and Bills Receivables

	As at June 30, 2022	
	<i>RMB'000</i>	<i>B'000</i>
	(unaudited)	(unaudited)
Trade receivables	1,865,656	275,717
Bills receivable	12,937	1,917
Less: provision for doubtful debts	(94,403)	(13,817)
	1,784,190	263,817

2022年6月30日，本公司及附属公司之应收款项及应收账款之账龄分析如下：

2022年6月30日，本公司及附属公司之应付账款之账龄分析如下：

	As at June 30, 2022 RMB'000 (unaudited)	美元 '000 (unaudited)
应付账款	1,745,500	267,110
应付账款	63,003	9,540
应付账款	63,555	9,640
应付账款	6,535	990
	<u>1,878,593</u>	<u>286,280</u>
应付账款	(94,403)	(14,250)
	<u><u>1,784,190</u></u>	<u><u>272,030</u></u>

2022年6月30日，本公司及附属公司之应付账款之账龄分析如下：

	As at June 30, 2022 RMB'000 (unaudited)	美元 '000 (unaudited)
应付账款	86,299	13,080
应付账款	6,905	1,040
应付账款	-	-
应付账款	1,199	180
	<u>94,403</u>	<u>14,280</u>

12. Trade Payables

	As at	
	June 30,	
	2022	
	RMB'000	B'000
	(unaudited)	(1,467,296)
Trade payables	554,266	1,467,296

As at June 30, 2022, trade payables are primarily due within 12 months and are classified as current liabilities. The carrying amount of trade payables is denominated in RMB.

	As at	
	June 30,	
	2022	
	RMB'000	B'000
	(unaudited)	(1,467,296)
Trade receivables	551,662	1,467,296
Other receivables	1,457	1,467,296
Prepaid expenses	287	1,467,296
Other receivables	860	1,467,296
	554,266	1,467,296

As at June 30, 2022, other receivables are primarily due within 12 months and are classified as current liabilities. The carrying amount of other receivables is denominated in RMB.

13. Share Capital

	As at	
	June 30,	
	2022	
	RMB'000	B'000
	(unaudited)	(1,467,296)
Share capital	1,467,296	1,467,296

Use of Proceeds from the H Share Listing of the Company

Listing Date, Prospectus, %

Use of proceeds

Use of proceeds (RMB million)	Net proceeds from Global Offering	Utilised as at June 30, 2022	Remaining amount	Expected time of use
11	1,214.5	1,214.5	0	Completed
12	1,214.5	0	1,214.5	Within 12 months
13	0	0	0	Completed
14	0	1,214.5	0	Completed
15	1,214.5	1,214.5	0	Completed
16	1,214.5	1,214.5	0	Completed
17	1,214.5	1,214.5	0	Completed
18	1,214.5	1,214.5	0	Completed
19	1,214.5	1,214.5	0	Completed
20	1,214.5	1,214.5	0	Completed
21	1,214.5	1,214.5	0	Completed
22	1,214.5	1,214.5	0	Completed
23	1,214.5	1,214.5	0	Completed
24	1,214.5	1,214.5	0	Completed
25	1,214.5	1,214.5	0	Completed
26	1,214.5	1,214.5	0	Completed
27	1,214.5	1,214.5	0	Completed
28	1,214.5	1,214.5	0	Completed
29	1,214.5	1,214.5	0	Completed
30	1,214.5	1,214.5	0	Completed
31	1,214.5	1,214.5	0	Completed
32	1,214.5	1,214.5	0	Completed
33	1,214.5	1,214.5	0	Completed
34	1,214.5	1,214.5	0	Completed
35	1,214.5	1,214.5	0	Completed
36	1,214.5	1,214.5	0	Completed
37	1,214.5	1,214.5	0	Completed
38	1,214.5	1,214.5	0	Completed
39	1,214.5	1,214.5	0	Completed
40	1,214.5	1,214.5	0	Completed
41	1,214.5	1,214.5	0	Completed
42	1,214.5	1,214.5	0	Completed
43	1,214.5	1,214.5	0	Completed
44	1,214.5	1,214.5	0	Completed
45	1,214.5	1,214.5	0	Completed
46	1,214.5	1,214.5	0	Completed
47	1,214.5	1,214.5	0	Completed
48	1,214.5	1,214.5	0	Completed
49	1,214.5	1,214.5	0	Completed
50	1,214.5	1,214.5	0	Completed
51	1,214.5	1,214.5	0	Completed
52	1,214.5	1,214.5	0	Completed
53	1,214.5	1,214.5	0	Completed
54	1,214.5	1,214.5	0	Completed
55	1,214.5	1,214.5	0	Completed
56	1,214.5	1,214.5	0	Completed
57	1,214.5	1,214.5	0	Completed
58	1,214.5	1,214.5	0	Completed
59	1,214.5	1,214.5	0	Completed
60	1,214.5	1,214.5	0	Completed
61	1,214.5	1,214.5	0	Completed
62	1,214.5	1,214.5	0	Completed
63	1,214.5	1,214.5	0	Completed
64	1,214.5	1,214.5	0	Completed
65	1,214.5	1,214.5	0	Completed
66	1,214.5	1,214.5	0	Completed
67	1,214.5	1,214.5	0	Completed
68	1,214.5	1,214.5	0	Completed
69	1,214.5	1,214.5	0	Completed
70	1,214.5	1,214.5	0	Completed
71	1,214.5	1,214.5	0	Completed
72	1,214.5	1,214.5	0	Completed
73	1,214.5	1,214.5	0	Completed
74	1,214.5	1,214.5	0	Completed
75	1,214.5	1,214.5	0	Completed
76	1,214.5	1,214.5	0	Completed
77	1,214.5	1,214.5	0	Completed
78	1,214.5	1,214.5	0	Completed
79	1,214.5	1,214.5	0	Completed
80	1,214.5	1,214.5	0	Completed
81	1,214.5	1,214.5	0	Completed
82	1,214.5	1,214.5	0	Completed
83	1,214.5	1,214.5	0	Completed
84	1,214.5	1,214.5	0	Completed
85	1,214.5	1,214.5	0	Completed
86	1,214.5	1,214.5	0	Completed
87	1,214.5	1,214.5	0	Completed
88	1,214.5	1,214.5	0	Completed
89	1,214.5	1,214.5	0	Completed
90	1,214.5	1,214.5	0	Completed
91	1,214.5	1,214.5	0	Completed
92	1,214.5	1,214.5	0	Completed
93	1,214.5	1,214.5	0	Completed
94	1,214.5	1,214.5	0	Completed
95	1,214.5	1,214.5	0	Completed
96	1,214.5	1,214.5	0	Completed
97	1,214.5	1,214.5	0	Completed
98	1,214.5	1,214.5	0	Completed
99	1,214.5	1,214.5	0	Completed
100	1,214.5	1,214.5	0	Completed

Significant Investments

During the reporting period, the Company has not made any significant investments. The Company's investments are primarily in the form of equity investments in its subsidiaries and joint ventures.

Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

The Company has not made any material acquisitions or disposals of subsidiaries, associates or joint ventures during the reporting period.

Events after the Reporting Period

There are no events after the reporting period that have a material effect on the Company's financial position, performance or cash flows.

Employee and Remuneration Policy

The Company's remuneration policy is designed to attract, retain and motivate key employees. The policy is based on performance and is subject to the approval of the Board of Directors. The remuneration of key employees is disclosed in the remuneration report. The Company's remuneration policy is consistent with the principles of the Corporate Governance Code.

Purchase, Sale or Redemption of Listed Securities

The Company has not purchased, sold or redeemed any listed securities during the reporting period.

Compliance with Corporate Governance Code

The Company is committed to high standards of corporate governance and is fully compliant with the Corporate Governance Code. The Company's corporate governance practices are consistent with the principles of the Code. The Company's compliance with the Code is detailed in the Corporate Governance Report.

The Company's corporate governance practices are consistent with the principles of the Corporate Governance Code. The Company's compliance with the Code is detailed in the Corporate Governance Report.

Compliance with the Model Code for Securities Transactions by Directors of Listed Issuers

... (Model Code) ...

Review of Interim Results by the Audit Committee

... (Audit Committee) ...

...

Interim Dividends

...

Publication of Interim Results Announcement and Interim Report 2022

...

Appreciation

...

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li

C

...

A, C
C, D, C, C, J

G, G

G, I

B, C
F, G